FDA approved Novo Nordisk A/S' Wegovy pill (25mg oral semaglutide) for weight loss. 16.6% mean weight loss in trial.
The FDA recently approved Novo Nordisk A/S' Wegovy pill, containing 25 mg of oral semaglutide, as a weight management treatment. This marks the first approval of an oral glucagon-like peptide-1 (GLP-1) receptor agonist for weight management. Clinical trials such as OASIS 4 showed that the pill led to a 16.6% mean weight loss in adults with obesity or overweight with comorbidities. The pill's efficacy was comparable to the injectable version of Wegovy at 2.4 mg, with one in three participants experiencing a 20% or greater weight reduction. Novo Nordisk plans to launch the Wegovy pill soon.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments